» Articles » PMID: 29915582

Imbalance of Circulating T17 and Regulatory T Cells in Alzheimer's Disease: A Case Control Study

Overview
Journal Front Immunol
Date 2018 Jun 20
PMID 29915582
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The neuropathological hallmarks of Alzheimer's disease (AD), i.e., neuritic plaques and neurofibrillary tangles, consist of beta amyloid peptides (Aβ) and hyperphosphorylated Tau. These are accompanied by reactive microglia and astrocytes in the vicinity of the neuritic plaques and by changes to the peripheral immune system, e.g., an increase of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the peripheral blood. To address a potential involvement of peripheral T helper cell (T) subsets in AD, we conducted a case control study with 54 individuals with AD dementia ( = 14), with mild cognitive impairment (MCI) due to AD (MCI,  = 14), with MCI unlikely due to AD (MCI,  = 13), and controls without cognitive impairment (controls,  = 13). The proportions of CD3CD8IL-17AIFNγ Th17 cells, CD3CD8IL-17AIFNγ Th1 cells, and CD4CD127CD25 regulatory T cells (T) were assessed by flow cytometry. In addition, the correlations of the proportions of T subsets to cerebrospinal fluid biomarkers were studied. CD3CD8IL-17AIFNγ Th17 cells were significantly increased in subjects with MCI compared to age- and sex-matched subjects with MCI and controls (MCI mean = 1.13, SD = 0.77; MCI mean = 0.58, SD = 0.28; and controls mean = 0.52, SD = 0.22;  = 0.008). The proportion of CD4CD127CD25 T was not altered between the different groups, but it significantly positively related with the levels of total Tau and pTau181 ( = 0.43,  = 0.021,  = 28;  = 0.46;  = 0.024,  = 28) in subjects with AD but not in nonAD controls (  -0.51,  = 0.007,  = 26). The increase of circulating CD3CD8IL-17AIFNγ Th17 cells in the early stages of AD and the association of CD4CD127CD25 T with neurodegeneration marker Tau may indicate that the adaptive immune system relates to neuropathological changes in AD.

Citing Articles

Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?.

Abbott V, Housden B, Houldsworth A Brain Commun. 2025; 7(2):fcaf092.

PMID: 40078868 PMC: 11896979. DOI: 10.1093/braincomms/fcaf092.


Brain interleukins and Alzheimer's disease.

Abdelhamed H, Hassan A, Sakraan A, Al-Deeb R, Mousa D, Aboul Ezz H Metab Brain Dis. 2025; 40(2):116.

PMID: 39891777 PMC: 11787210. DOI: 10.1007/s11011-025-01538-5.


Elevated BACE1 and IFNγ+ T Cells in Patients with Cognitive Impairment and the 5xFAD Mouse Model.

Zhan Y, Chen Z, Zheng S, Dai L, Zhang W, Dai Y ACS Chem Neurosci. 2025; 16(3):384-392.

PMID: 39810314 PMC: 11804866. DOI: 10.1021/acschemneuro.4c00565.


Peripheral Single-Cell Immune Characteristics Contribute to the Diagnosis of Alzheimer's Disease and Dementia With Lewy Bodies.

Qiu C, Zhang D, Wang M, Mei X, Chen W, Yu H CNS Neurosci Ther. 2025; 31(1):e70204.

PMID: 39754303 PMC: 11702477. DOI: 10.1111/cns.70204.


Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine.

Mashima E, Saito-Sasaki N, Sawada Y Diagnostics (Basel). 2024; 14(20).

PMID: 39451595 PMC: 11506695. DOI: 10.3390/diagnostics14202272.


References
1.
Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif A, Spinrad A . Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun. 2015; 6:7967. PMC: 4557123. DOI: 10.1038/ncomms8967. View

2.
Thal D, Capetillo-Zarate E, Del Tredici K, Braak H . The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006; 2006(6):re1. DOI: 10.1126/sageke.2006.6.re1. View

3.
Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E . Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology. 2005; 65(9):1502-3. DOI: 10.1212/01.wnl.0000183284.92920.f2. View

4.
Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo J, Eusebi P . Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis. 2016; 55(2):813-822. PMC: 5147502. DOI: 10.3233/JAD-160722. View

5.
Fisher Y, Nemirovsky A, Baron R, Monsonego A . T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One. 2010; 5(5):e10830. PMC: 2877087. DOI: 10.1371/journal.pone.0010830. View